Clinical Trial

Facilitating Rapid Naltrexone Initiation

Study Description

Facilitating Rapid Naltrexone Initiation

The incidence of opioid use disorders (OUDs) has increased to near-epidemic proportions. While maintenance with long-acting opioids such as methadone or buprenorphine represents an effective treatment strategy, it may be unacceptable to many individuals. As a result, long-acting injectable naltrexone (XR-NTX), an antagonist medication that blocks the effects of opioids for at least 4 weeks, is now indicated for relapse prevention following detoxification. This randomized, controlled trial aims to test the efficacy of a glutamate modulator at facilitating a rapid non-opioid based naltrexone induction.

Location

Locations Selected Location

Methods

Pharmaceutical medication involved Pharmaceutical medication involved
Patients and healthy individuals accepted Patients and healthy individuals accepted

Drug - CI-581-a

Two infusions in the context of naltrexone induction protocol.

Drug - CI-581-b

Two infusions in the context of naltrexone induction protocol.

Additional Information

Official Study Title

Glutamatergic Modulation to Facilitate Naltrexone Initiation: A Randomized, Controlled Trial

Clinical Trial ID

NCT03345173

ParticipAid ID

9aA51a